Morbidity and mortality of vulvar and vaginal cancers: Impact of 2-, 4-, and 9-valent HPV vaccines
Open Access
- 18 February 2016
- journal article
- review article
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 12 (6) , 1352-1356
Abstract
Vaginal and vulvar cancers do not account for a large proportion of gynecologic malignancies but their impact is significant. Both vaginal and vulvar lesions have precursors and display levels of dysplasia before progression to invasive disease. Human Papillomavirus (HPV) is a known causative agent of such dysplasia and can be detected now more readily than ever with adequate recognition techniques and provider awareness. Although HPV vaccination is still lagging compared to other recommended childhood vaccinations, the impact on lower genital tract neoplasia is promising. The bivalent and quadrivalent vaccines have been shown to be efficacious and the newest nonavalent vaccine should add even more of impact on coverage of cancer-causing HPV types. Although it is still early to show true clinical and population-based disease reduction due to low disease incidence and relatively short time of vaccine availability, the potential is noteworthy.Keywords
This publication has 31 references indexed in Scilit:
- Cancer statistics, 2013CA: A Cancer Journal for Clinicians, 2013
- Potential impact of a nine-valent vaccine in human papillomavirus related cervical diseaseInfectious Agents and Cancer, 2012
- Fall in Human Papillomavirus Prevalence Following a National Vaccination ProgramThe Journal of Infectious Diseases, 2012
- Role of AS04 in human papillomavirus vaccine: mode of action and clinical profileExpert Opinion on Biological Therapy, 2011
- Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young womenThe Lancet, 2009
- The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus‐Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Sexually Active Women Aged 16–26 YearsThe Journal of Infectious Diseases, 2009
- Outcomes After Diagnosis of Vaginal Intraepithelial NeoplasiaJournal of Lower Genital Tract Disease, 2008
- Long-term efficacy of human papillomavirus vaccinationGynecologic Oncology, 2007
- Trends in the Incidence of Invasive and In Situ Vulvar CarcinomaObstetrics & Gynecology, 2006
- Effect of antiretroviral therapy on the incidence of genital warts and vulvar neoplasia among women with the human immunodeficiency virusAmerican Journal of Obstetrics and Gynecology, 2004